GlassScriptPhysician profile
Brian D Jenkins
NPI 1497725295
$93,237.21
in general payments reported to CMS, 2019-2025
52 companies · $623 in 2025
The $623 reported for 2025 was more than what 87% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $22K · 2021: $31K · 2022: $1,708 · 2023: $8,735 · 2024: $2,429 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,625 · Food and Beverage: $2,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,625.00 |
| Food and Beverage | $2,162.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $50,713.51 | 2019-2022 | |
| Lundbeck LLC | $12,532.34 | 2020-2025 | Vyepti |
| Abbvie INC. | $11,346.23 | 2019-2025 | |
| Amgen INC. | $11,298.58 | 2019-2024 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $3,348.65 | 2019-2025 | Austedo Xr, Ajovy |
| Biohaven Pharmaceuticals, INC. | $1,665.09 | 2021 | |
| Novartis Pharmaceuticals Corporation | $294.35 | 2019-2025 | |
| Biogen, INC. | $179.90 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Sk Life Science, INC. | $171.57 | 2022-2024 | |
| Pfizer INC. | $149.50 | 2023-2025 | |
| Emd Serono, INC. | $143.89 | 2019-2024 | |
| Ucb, INC. | $109.93 | 2019-2025 | Zilbrysq |
| Lilly USA, LLC | $99.95 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Alexion Pharmaceuticals, INC. | $90.58 | 2019-2025 | Ultomiris, Soliris |
| Genentech USA, INC. | $84.96 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
Show all 49 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jenkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.